» Articles » PMID: 32103967

Failure to Reach a Consensus in Polypharmacy Definition: An Obstacle to Measuring Risks and Impacts-Results of a Literature Review

Overview
Publisher Dove Medical Press
Date 2020 Feb 28
PMID 32103967
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The risk of polypharmacy is on the rise in most industrialized countries, threatening to burden their health systems. Although many definitions exist and numerous concepts are found in literature as synonyms, the phenomenon of polypharmacy remains poorly defined. The aim of this literature review is to provide an overview of available definitions of polypharmacy, to analyse their convergences and divergences and to discuss the consequences on the assessment of the problem.

Methods: A literature review was conducted to identify all published systematic reviews on definitions of polypharmacy available via Scopus and Pubmed databases. The Assessment of Multiple Systematic Reviews (AMSTAR) tool was used to appraise the methodological quality of the selected reviews. Available definitions and other characteristics were extracted; summarised in a table and analysed.

Results: Six systematic reviews were identified. They were published between 2000 and 2018. Three focussed on definitions of polypharmacy in the elderly; two in the general population and one in children. The strategy adopted in reviews is more rigorous in the most recent ones. However, they remain, at best, partially exhaustive. The definitions found in the literature used two main approaches, either (i) quantitative, applying varying thresholds and types of polypharmacy based on the number of medications being taken by the patient (ii) qualitative, based on the clinical indications and effects of a given drug regimen, with a growing number of characteristics to describe polypharmacy. The term "inappropriate" is increasingly associated with polypharmacy especially in studies that aimed to use this definition to identify possible solutions for healthcare providers in the field related to aging.

Conclusion: This review confirms a high variability and an evolution in the approaches defining "polypharmacy" in the absence of a consensus following standardized criteria. That makes it very difficult to estimate and measure the outcomes associated with this phenomenon.

Citing Articles

The association between continuous polypharmacy and hospitalization, emergency department visits, and death in older adults: a nationwide large cohort study.

Chae J, Cho H, Yoon S, Kim D Front Pharmacol. 2024; 15:1382990.

PMID: 39144630 PMC: 11322047. DOI: 10.3389/fphar.2024.1382990.


Protocol for the development and validation of a Polypharmacy Assessment Score.

Tsang J, Sperrin M, Blakeman T, Payne R, Ashcroft D Diagn Progn Res. 2024; 8(1):10.

PMID: 39010248 PMC: 11251249. DOI: 10.1186/s41512-024-00171-7.


Defining, identifying and addressing problematic polypharmacy within multimorbidity in primary care: a scoping review.

Tsang J, Sperrin M, Blakeman T, Payne R, Ashcroft D BMJ Open. 2024; 14(5):e081698.

PMID: 38803265 PMC: 11129052. DOI: 10.1136/bmjopen-2023-081698.


Comprehensive Analysis of Drug Utilization Patterns, Gender Disparities, Lifestyle Influences, and Genetic Factors: Insights from Elderly Cohort Using g-Nomic Software.

Rodriguez Castillo B, Cendros M, Ciudad C, Sabater A Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794134 PMC: 11123674. DOI: 10.3390/ph17050565.


Potentially modifiable factors associated with health-related quality of life among people with chronic kidney disease: baseline findings from the National Unified Renal Translational Research Enterprise CKD (NURTuRE-CKD) cohort.

Phillips T, Harris S, Aiyegbusi O, Lucas B, Benavente M, Roderick P Clin Kidney J. 2024; 17(2):sfae010.

PMID: 38313684 PMC: 10836575. DOI: 10.1093/ckj/sfae010.


References
1.
Burt J, Elmore N, Campbell S, Rodgers S, Avery A, Payne R . Developing a measure of polypharmacy appropriateness in primary care: systematic review and expert consensus study. BMC Med. 2018; 16(1):91. PMC: 5998565. DOI: 10.1186/s12916-018-1078-7. View

2.
Barnett K, McCowan C, Evans J, Gillespie N, Davey P, Fahey T . Prevalence and outcomes of use of potentially inappropriate medicines in older people: cohort study stratified by residence in nursing home or in the community. BMJ Qual Saf. 2011; 20(3):275-81. DOI: 10.1136/bmjqs.2009.039818. View

3.
Kojima T, Akishita M, Nakamura T, Nomura K, Ogawa S, Iijima K . Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int. 2012; 12(3):425-30. DOI: 10.1111/j.1447-0594.2011.00783.x. View

4.
Hersh L, Beldowski K, Hajjar E . Polypharmacy in the Geriatric Oncology Population. Curr Oncol Rep. 2017; 19(11):73. DOI: 10.1007/s11912-017-0632-3. View

5.
Gillette C, Prunty L, Wolcott J, Broedel-Zaugg K . A new lexicon for polypharmacy: Implications for research, practice, and education. Res Social Adm Pharm. 2014; 11(3):468-71. DOI: 10.1016/j.sapharm.2014.08.010. View